Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (November 2026)
45 slides from Recce Pharmaceuticals's investor presentation, November 2026

Slide 1: RCE Corporate Presentation
RCE Corporate Presentation ASX:RCE | FSE:R9Q November 2026 0

Slide 2: Disclaimer
Disclaimer DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the information that a prospecti

Slide 3: Company Overview
Company Overview

Slide 4: Recce Pharmaceuticals – Company Overview
Recce Pharmaceuticals – Company Overview Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics and against multidrug

Slide 5: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sc i), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Technologies,

Slide 6: Capital Structure and Share Price
Capital Structure and Share Price Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – November 2026 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) ASX & FSE Code RCE, R9Q 12,000,000 $0.80 Share Price

Slide 7: The Advantages of a New Class of Antibiotics
The Advantages of a New Class of Antibiotics Recce is on-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens Unprecedented, broad-spectrum activity against Gram-positive and Gram-negative bacteria Universal Mechanism of

Slide 8: Large Addressable Market US$5.8B
Large Addressable Market The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems INDONESIA MENA GLOBAL US$5.8B >20 million adults in Indonesia with >84 million adults in MENA region >589 million adults globally with Est. global DFI diabetes3 with

Slide 9: Company Pipeline driven by 1st approval in Diabetic Foot Infections
Company Pipeline driven by 1st approval in Diabetic Foot Infections 2026 2027 Core Programs 155-patient R327G R327G Registrational Phase 3 trial recruitment interim analysis registrable registrable and dosing continue uninterrupted and readout in Indonesia in ASEAN R327G Topical Diabetic foot infect

Slide 10: Commercial & Licensing
Commercial & Licensing 9

Slide 11: Australia and New Zealand Licence Agreement
Australia and New Zealand Licence Agreement Recce has signed a binding exclusive licence agreement with Arrotex Pharmaceuticals to commercialise R327G A direct commercial route for R327G in Australia and New Zealand Agreement Highlights Partnership with Arrotex Pharmaceuticals Commercial Costs Cover

Slide 12: Middle Eastern Pharmaceutical Company Term Sheet
Middle Eastern Pharmaceutical Company Term Sheet Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive multi-country licensing agreement for the licensing of R327G through the MENA region Term Sheet Highlights • The MENA region has a d

Slide 13: RECCE 327 Synthetic Anti-Infective
RECCE® 327 Synthetic Anti-Infective 12

Slide 14: Independent Study Undertaken on RECCE 327 MoA
Independent Study Undertaken on RECCE® 327 MoA1 Linnaeus Biosciences MoA studies of R327 Novel mechanism which targets rapid access to and shut down of bacterial energy production (ATP), which results in bacterial death of both active and resting bacteria. Stage 2 Stage 4 Stage 1 Stage 3 R327 target

Slide 15: RECCE 327 Maintains Activity
RECCE® 327 Maintains Activity Amoxicillin loses activity after a maximum of 8 repeats; RECCE ® 327 remains active for more than 25 repeats 25 repeats at time of discovery was sufficient for PCT patent applications, with no sign of resistance. Number of repeats before displaying loss of antibiotic ac

Slide 16: Bactericidal Effect of RECCE 327 on ESKAPE Pathogens
Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens E. faecium ATCC 19434 S. aureus ATCC 29213 K. pneumoniae ATCC 43816 A. baumannii ATCC 17978 P. aeruginosa ATCC 27853 Enterobacter cloacae ATCC 13047 • Average time-kill curves of R327 at various concentrations against strains of ESKAPE pathogens

Slide 17: RECCE 327 Topical Gel
RECCE® 327 Topical Gel 16

Slide 18: RECCE Topical Gel
RECCE® 327 Topical Gel First-Line Local Treatment for Infected Wounds No Pathogen Identification Required Rapid Clinical Response • Applied directly to infected tissue • Clinical and TGA Special Access Scheme use demonstrates visible reduction in • Localised antimicrobial action at the site of infec

Slide 19: DFIs: Addressing a High-Burden Infection Setting
DFIs: Addressing a High-Burden Infection Setting DFIs are complex infection Local infection RECCE® 327G was designed environments management in DFIs with DFI complexity in mind • Compromised blood flow, impaired • Direct delivery of anti-infective • Designed for direct application immune response an

Slide 20: Dual Phase 3 Clinical Trial Strategy
Dual Phase 3 Clinical Trial Strategy Two Phase 3 Clinical Trials, in Australia and Indonesia Indonesia Phase 3 Australia Phase 3 Registrational, multi-centre, double-blind, placebo-controlled Conducted to TGA and US FDA regulatory standards, Active- comparator design: R327G versus one of four physic

Slide 21: Regulatory Acceleration & ASEAN Commercial Entry
Regulatory Acceleration & ASEAN Commercial Entry High-Impact • ~20M people living with diabetes Market • In Indonesia, DFIs are severe in 67.1% of hospitalised cases and result in amputation in 46.9% of patients1. • In-hospital treatment costs averaging IDR 64.95 million (USD ~$4,100) per patient1.

Slide 22: Registrational Phase 3 Clinical Trial - Indonesia
Registrational Phase 3 Clinical Trial - Indonesia Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections Population Up to 310 participants will Intervention be enrolled who present with a mild diabetic foot infection. Part

Slide 23: Indonesia Phase 3: Independent DMC Review Underway
Indonesia Phase 3: Independent DMC Review Underway Blinded Data across 75 patients has shown • Review of the blinded data indicates strong efficacy across the study population 75 90 • RECCE® 327 Gel (R327G) continues to demonstrate Patients submitted for Patients currently enrolled an excellent safe

Slide 24: Phase 3 DFI Clinical Trial Expands in Australia
Phase 3 DFI Clinical Trial Expands in Australia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority component ~80% HREC approval significantly expands DFI Total Mild + Moderate patient pool from Mild to Mild + Moderate 47% Mild DFI Was Now Ulcer Below ankle Below k

Slide 25: Phase 3 DFI Clinical Trial in Australia
Phase 3 DFI Clinical Trial in Australia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component Protocol amendment adds moderate DFI. Mild and Moderate DFI together represent 80% of DFI presentations. Head-to-head comparison against existing a

Slide 26: Topical Clinical Programs – Previously Completed
Topical Clinical Programs – Previously Completed • Interim data results released – primary endpoints achieved Phase I/II • Patients supported by in-home (out-patient) nurses trained in Clinical Trial R327 treatment protocols Diabetic Foot • Study across South Western Sydney health district – one of

Slide 27: Phase II ABSSSI Clinical Trial Achieved all Endpoints
Phase II ABSSSI Clinical Trial Achieved all Endpoints Study: Phase II study as an open-label clinical trial evaluating the safety and tolerability, efficacy, and plasma pharmacokinetics of R327G when applied directly to the infected area NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNI

Slide 28: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 1 Day 30 Day 0 – Recce treatment Day 0 – Recce treatment Day 1 – Recce treatment Day 30 – Recce treatment Pre-treatment infection First Recce gel applied Post treatment Post treatment • Patient A unresponsive to 4x daily Cepha

Slide 29: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 14 Day 10 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Wound drying up Post treatment Wound improved, well tolerated • Pre-treatment of R327G

Slide 30: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment • Pre-treatment wound swab on Day 0 showed a growing culture ✓ Day 21 post-treatment, the wound had of both G

Slide 31: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Significant bacterial infection Redness and swelling Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment of R327G showed significant bacterial infection, ✓ Day 7 post-treatment showed wound

Slide 32: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment (Day 0) X-rays showed infection deep within the ✓ Day 7 post R327G treatment showed wound underlying bone, tissue and around the nail, wit

Slide 33: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 5 Significant bacterial infection Day 0 – Pre-treatment Day 5 – Recce treatment • Significant bacterial infection – septic ankle arthritis, peri- ✓ The discharge has cleared, and with no signs Left femoral prosthetic joint infection

Slide 34: RECCE 327 Clinical Programs
RECCE® 327 Clinical Programs 37

Slide 35: R327 Faster Acting Than Existing Antibiotics
R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed R327 is faster-acting against bacteria than other antibiotics – works quickly, without prolonged cellular exposure times required of other antibiotics (extended exposures commonly associated with systemic toxicity). R327 desig

Slide 36: RECCE 327 Summary Results – Phase I – Complete
RECCE® 327 Summary Results – Phase I – Complete Double-blind, Placebo-controlled, Single Ascending-dose, Safety and Pharmacokinetic Study in Healthy Participants ✓ Safe and well tolerated at doses up to 6,000mg given as a 1-hour intravenous infusion; ✓ No Serious Adverse Events; – All AE’s mild or m

Slide 37: RECCE Concentrates Safely in the Urine
RECCE® 327 Concentrates Safely in the Urine Concentration of R327 Ratio Urine/Plasma in Urine Compared to Plasma 16x 17x 14x 9x In over 60 21x healthy subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney to

Slide 38: RECCE Kills Quickly in the Urine
RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine • R327 in the presence of human urine was able to have 10.00 a fast (near minutes) effect against E. coli and irreversible 9.00 Viable Bacteria (log CFU/ml) • Bacteria could not be revived post-treatment 8.00 •

Slide 39: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial UTIs are responsible for about 30% of all sepsis infections, defined as ‘Urosepsis’ Clinical Trial Complete R327 has achieved multiple ‘fast infusion’ time stamps in line with intended future Assessment Assessing R327 at faster administration ra

Slide 40: Intellectual Property & Manufacturing
Intellectual Property & Manufacturing 43

Slide 41: Robust Worldwide Intellectual Property Portfolio
Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Patent Filed Expiry Expiry Expiry Expiry Family 1 Family 2 Family 3 Family 4 Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041 Family 1 gr

Slide 42: Manufacturing & Scalability
Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park Raw materials No expensive waste Automated manufacture process Plentiful and cheap – few 99.9% product yield Completing 5,000 doses a $/Kg week under GMP Clear benefits in cost GMP Manufacturing Capability to and scalabili

Slide 43: RECCE 327 – Global Recognition
RECCE® 327 – Global Recognition R327 added to World Health Organization’s List of Antibacterial Products in Clinical Development • Global recognition by the World Health Organization (WHO) – inclusion underscores significance of R327 in combating antimicrobial resistance. • Unique Mechanism of Actio

Slide 44: Progress with the U.S. Department of War
Progress with the U.S. Department of War Collaboration with the U.S. Department of War in advancing next-generation of anti-infectives U.S. Army Medical CDMRP Grant US$2 million 1st CRADA Research Institute of 2nd CRADA – Feb 2026 Infectious Diseases (USAMRIID) Congressionally Directed Medical Coope

Slide 45: Thank you
Thank you @0@ recce.com.au
Source: company website
More decks from Recce Pharmaceuticals Ltd.
Shareholder Meeting (November 2026)19 slides · Nov 6, 2026
Investor Presentation (October 2026)42 slides · October 2026
Shareholder Meeting (September 2026)10 slides · Sep 2, 2026
Investor Presentation (September 2026)42 slides · September 2026
Investor Presentation (August 2026)40 slides · August 2026
Q4 FY26 Earnings Presentation17 slides · Jul 21, 2026